These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 6316668)
1. [Clinical use of new cephalosporins for severe infections in internal medicine]. Stille W Wien Klin Wochenschr Suppl; 1983; 142():18-20. PubMed ID: 6316668 [TBL] [Abstract][Full Text] [Related]
2. [In-vitro activity of cefotaxime]. Knothe H Wien Klin Wochenschr Suppl; 1983; 142():4-7. PubMed ID: 6316671 [TBL] [Abstract][Full Text] [Related]
3. [Preventive and therapeutic application possibilities of newer antibiotics (author's transl)]. Marget W MMW Munch Med Wochenschr; 1979 Sep; 121(36):1133-6. PubMed ID: 114782 [TBL] [Abstract][Full Text] [Related]
5. [Cefotaxime in digestive tract infections (author's transl)]. Paris J; Paris JC; Gérard A Nouv Presse Med; 1981 Feb; 10(8):647-9. PubMed ID: 6259611 [TBL] [Abstract][Full Text] [Related]
6. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. Ko WC; Lee HC; Chuang YC; Liu CC; Wu JJ J Infect; 2000 May; 40(3):267-73. PubMed ID: 10908022 [TBL] [Abstract][Full Text] [Related]
7. Gentamicin therapy administered by intermittent intravenous injections. Korner B Acta Pathol Microbiol Scand B Microbiol Immunol; 1973; ():Suppl 241:15-2. PubMed ID: 4521603 [No Abstract] [Full Text] [Related]
8. Recent advances in chemotherapy. Murdoch JM; Geddes AM; Munro JF S Afr Med J; 1968 Jan; 42(3):54-7. PubMed ID: 5638047 [No Abstract] [Full Text] [Related]
9. The newer antibiotics: some therapeutic considerations. Bullock WE J Ky Med Assoc; 1972 Feb; 70(2):109-13. PubMed ID: 5016961 [No Abstract] [Full Text] [Related]
10. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813 [TBL] [Abstract][Full Text] [Related]
11. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations. Wilson WR; Bouza E; Lode H; Mouton Y J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972 [TBL] [Abstract][Full Text] [Related]
12. [In vitro activity of a new cephalosporin--cefoperazone--against Enterobacteriaceae and Pseudomonas aeruginosa]. Modde H Schweiz Med Wochenschr; 1981 Mar; 111(10):356-8. PubMed ID: 6452690 [TBL] [Abstract][Full Text] [Related]
13. [Cefotaxime in septicaemia and severe infections due to multiresistant Gram-negative bacilli (author's transl)]. Dureux JB; Canton P; Roche G; Weber M; Gérard A Nouv Presse Med; 1981 Feb; 10(8):601-6. PubMed ID: 6259602 [TBL] [Abstract][Full Text] [Related]
17. Carbenicillin plus cephalothin or cefazolin as therapy for infections in neutropenic patients. Bodey GP; Valdivieso M; Feld R; Rodriguez V; McCredie K Am J Med Sci; 1977; 273(3):309-18. PubMed ID: 326048 [No Abstract] [Full Text] [Related]
18. [Nosocomial bacteria: profiles of resistance]. Sow AI Dakar Med; 2005; 50(1):7-9. PubMed ID: 16190117 [TBL] [Abstract][Full Text] [Related]
19. Treatment with gentamicin. Application and therapeutic effect. Belfrage S; Banck G; Nordström L Acta Pathol Microbiol Scand B Microbiol Immunol; 1973; ():Suppl 241:62-4. PubMed ID: 4521608 [No Abstract] [Full Text] [Related]